×
About 3,153 results

ALLMedicine™ IgA Nephropathy Center

Research & Reviews  1,181 results

Multi-organ involvement and intratubular calcium phosphate deposition in the kidney bio...
https://doi.org/10.1007/s40519-022-01406-6 10.1016/S2215-0366(15)00356-9 10.1309/2Y7X-YDXK-006B-XLT2 10.1258/acb.2011.011185 10.3390/ijms20112712 10.1016/j.kint.2018.02.030
Eating and Weight Disorders : EWD; Suarez GMG, Merino-Ribas A et. al.

May 14th, 2022 - Anorexia nervosa is frequently associated with alcohol use disorder. Both of them may adversely affect almost every body system, leading to worse clinical outcomes and high mortality risk. Nonetheless, there is little evidence interrelating anorex...

Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
https://clinicaltrials.gov/ct2/show/NCT04578834

May 13th, 2022 - This trial is a multicenter, randomized, double-blind, placebo controlled parallel group study. The purpose of the study is to evaluate the efficacy and safety of LNP023 compared to placebo on proteinuria reduction and slowing disease progression ...

Factor H-Related Protein 1 Drives Disease Susceptibility and Prognosis in C3 Glomerulop...
https://doi.org/10.1681/ASN.2021101318
Journal of the American Society of Nephrology : JASN; Márquez-Tirado B, Gutiérrez-Tenorio J et. al.

May 12th, 2022 - C3 glomerulopathy (C3G) is a heterogeneous group of chronic renal diseases characterized predominantly by glomerular C3 deposition and complement dysregulation. Mutations in factor H-related (FHR) proteins resulting in duplicated dimerization doma...

Effectiveness and safety of KunXian capsule for the treatment of IgA nephropathy.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088128
BMC Nephrology; Le WB, Shi JS et. al.

May 11th, 2022 - Tripterygium Wilfordii Hook F (TwHF) preparation has been widely used in the treatments of IgA nephropathy (IgAN) in China. However, the effectiveness and safety of the new generation of TwHF preparation, KuxXian capsule, on the treatment of IgAN ...

Recurrence of IgA nephropathy after kidney transplantation: experience from the Swiss t...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088042
BMC Nephrology; Jäger C, Stampf S et. al.

May 11th, 2022 - Recurrence of IgA nephropathy (IgAN) after kidney transplantation occurs in about 30% of patients. The relevance of recurrence for the long-term graft survival is expected to increase, since graft survival continues to improve. In a nested study w...

see more →

Guidelines  3 results

A digest from evidence-based clinical practice guideline for IgA nephropathy 2020.
https://doi.org/10.1007/s10157-021-02095-8
Clinical and Experimental Nephrology; Suzuki H, Kikuchi M et. al.

Sep 27th, 2021 - A digest from evidence-based clinical practice guideline for IgA nephropathy 2020.|2021|Suzuki H,Kikuchi M,Koike K,Komatsu H,Matsuzaki K,|diagnosis,therapy,

Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.
https://doi.org/10.1016/j.kint.2021.05.015
Kidney International; Rovin BH, Adler SG et. al.

Sep 25th, 2021 - The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Glomerular Diseases is an update to the KDIGO 2012 guideline. The aim is to assist clinicians caring for individuals with glomerulonephritis (G...

Evidence-based clinical practice guidelines for IgA nephropathy 2014.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4956709
Clinical and Experimental Nephrology; Yuzawa Y, Yamamoto R et. al.

Apr 21st, 2016 - Evidence-based clinical practice guidelines for IgA nephropathy 2014.|2016|Yuzawa Y,Yamamoto R,Takahashi K,Katafuchi R,Tomita M,|diagnosis,etiology,therapy,

see more →

Clinicaltrials.gov  44 results

Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
https://clinicaltrials.gov/ct2/show/NCT04578834

May 13th, 2022 - This trial is a multicenter, randomized, double-blind, placebo controlled parallel group study. The purpose of the study is to evaluate the efficacy and safety of LNP023 compared to placebo on proteinuria reduction and slowing disease progression ...

Jinghua Weikang Capsule Containing Quadruple Therapy for IgAN With Helicobacter Pylori Infection
https://clinicaltrials.gov/ct2/show/NCT05320133

Apr 26th, 2022 - This study is to evaluate the efficacy and safety of the Jinghua Weikang Capsule (a Chinese patent medicine for peptic ulcer and gastritis) containing quadruple therapy (Jinghua Weikang Caplsule plus triple therpy) for eradicating Helicobacter pyl...

The Effects of Mycophenolate Mofetil (MMF) on Renal Outcomes in Advanced Immunoglobulin A (IgA) Nephropathy Patients
https://clinicaltrials.gov/ct2/show/NCT01854814

Apr 13th, 2022 - The study is to evaluate the effect of Mycophenolate Mofetil compared with losartan alone on time to doubling of serum creatinine or the onset of end stage renal disease in patients with advanced IgA nephropathy who are treated with the maximal to...

A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
https://clinicaltrials.gov/ct2/show/NCT03366337

Mar 24th, 2022 - This multi-center, open-label Phase 2 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with the following rare chronic kidney diseases (CKD): CKD associated with type 1 diabetes (T1D), IgA nephrop...

Study of the Link Between Complement Activation and IgA Nephropathy Severity
https://clinicaltrials.gov/ct2/show/NCT05234463

Mar 2nd, 2022 - IgA nephropathy (IgAN) is a common cause of glomerulonephritis and a major cause of end stage renal disease in up to 20-40% of patients. However, its prognosis still cannot be accurately predicted due to the high heterogenicity of clinical present...

see more →

News  29 results

FDA OKs First Proteinuria Drug for IgA Nephropathy
https://www.medpagetoday.com/nephrology/generalnephrology/96235

Dec 16th, 2021 - The FDA granted accelerated approval for the first drug to reduce proteinuria in primary immunoglobulin A (IgA) nephropathy, the agency announced on Wednesday. The delayed released budesonide (Tarpeyo) capsules are indicated to lower increased pro...

'Strong Evidence' Oral Steroids Slow IgA Nephropathy Progression
https://www.medscape.com/viewarticle/962639

Nov 10th, 2021 - Daily treatment of patients with IgA nephropathy with an oral glucocorticoid, methylprednisolone, led to significant reductions in the rate of kidney failure and a composite tally of adverse incident renal outcomes in a multicenter, randomized tri...

Complement Inhibitor Shows Early Promise in IgA Nephropathy
https://www.medscape.com/viewarticle/952739

Jun 9th, 2021 - A first-in-class oral inhibitor of the alternative complement pathway that drives the pathogenesis of primary glomerulonephritis, iptacopan (LNP023, Novartis), is showing early promise as the first targeted therapy for the treatment of IgA nephrop...

New DAPA-CKD Analysis Hints at Dapagliflozin for IgA Nephropathy
https://www.medscape.com/viewarticle/949579

Apr 20th, 2021 - Treatment with the sodium-glucose cotransporter-2 (SGLT2) inhibitor dapagliflozin (Farxiga) was safe and effective for slowing progression of chronic kidney disease (CKD) and the development of end-stage renal disease for patients with immunoglobu...

Severe renal arteriosclerosis may indicate cardiovascular risk in lupus nephritis
https://www.mdedge.com/rheumatology/article/234917/lupus-connective-tissue-diseases/severe-renal-arteriosclerosis-may
Heidi Splete

Jan 22nd, 2021 - Severe renal arteriosclerosis was associated with a ninefold increased risk of atherosclerotic cardiovascular disease in patients with lupus nephritis, based on data from an observational study of 189 individuals. Mohammed Haneefa Nizamudeen/Getty.

see more →

Patient Education  4 results see all →